secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0000875045-26-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance
--------------------------------------------------------------------------------

- Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.
- Full year total revenue $9.9B (+2% YoY); GAAP diluted EPS $8.79; Non-GAAP EPS $15.28 above $14.50-$15.00 guidance.
- Growth products up 6% YoY in Q4; LEQEMBI global in-market sales $134M (+54% YoY).
- FY2026 guidance: Non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit percent vs FY2025.
- Pipeline: LEQEMBI subcutaneous PDUFA May 24, 2026; litifilimab Breakthrough Therapy for CLE; high-dose SPINRAZA PDUFA Apr 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/0000875045-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/biib-20260206.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer